Myriad Patent Case Tees Up 2 Key Issues For High Court

Law360, New York (December 3, 2012, 9:45 PM EST) -- The U.S. Supreme Court's upcoming case on human gene patents gives the court a chance to provide guidance on the extent to which natural material must be altered before it can be covered by a patent and how courts should treat the past practice of the patent office when weighing patentability, attorneys said.

The justices agreed Friday to review a decision in which the Federal Circuit ruled that DNA isolated by Myriad Genetics Inc. could be patented because it is a man-made composition different from naturally...
To view the full article, register now.